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AbstrAct
Hexavalent Chromium [Cr(VI)] compounds are human lung carcinogens 
and environmental/occupational hazards. The molecular mechanisms of Cr(VI) 
carcinogenesis appear to be complex and are poorly defined. In this study, we 
investigated the potential role of Gene 33 (ERRFI1, Mig6), a multifunctional adaptor 
protein, in Cr(VI)-mediated lung carcinogenesis. We show that the level of Gene 33 
protein is suppressed by both acute and chronic Cr(VI) treatments in a dose- and 
time-dependent fashion in BEAS-2B lung epithelial cells. The inhibition also occurs in 
A549 lung bronchial carcinoma cells. Cr(VI) suppresses Gene 33 expression mainly 
through post-transcriptional mechanisms, although the mRNA level of gene 33 also 
tends to be lower upon Cr(VI) treatments. Cr(VI)-induced DNA damage appears 
primarily in the S phases of the cell cycle despite the high basal DNA damage signals 
at the G2M phase. Knockdown of Gene 33 with siRNA significantly elevates Cr(VI)-
induced DNA damage in both BEAS-2B and A549 cells. Depletion of Gene 33 also 
promotes Cr(VI)-induced micronucleus (MN) formation and cell transformation in 
BEAS-2B cells. Our results reveal a novel function of Gene 33 in Cr(VI)-induced DNA 
damage and lung epithelial cell transformation. We propose that in addition to its role 
in the canonical EGFR signaling pathway and other signaling pathways, Gene 33 may 
also inhibit Cr(VI)-induced lung carcinogenesis by reducing DNA damage triggered 
by Cr(VI).
INtrODUctION
Cr(VI) compounds are well documented human 
lung carcinogens [1-3]. Occupational exposure, mainly 
through inhalation, during industrial processes such as 
chrome plating, stainless steel production, and chrome 
pigment manufacturing are the main sources of human 
contact with Cr(VI) [1-3]. Cr(VI) is a genotoxic agent 
that induces DNA damage [2, 4-8]. The toxic effect of 
Cr(VI) is believed to be a result of oxidative stresses 
generated during its reduction process [7]. Exposure of 
cells to Cr(VI) provokes a typical DNA damage response 
that leads to cell cycle arrest, apoptosis, and senescence 
[4-6, 8-10]. Interestingly, despite the ability of forming 
potentially mutagenic Cr(III)-DNA ternary adducts during 
its intracellular reduction process [9], Cr(VI) appears to be 
a weak mutagen [5]. Consistently, lung cancers associated 
with Cr(VI) exposure exhibit few mutations of the key 
oncogenes or tumor suppressors [2]. The genotoxic effect 
of Cr(VI) is more likely represented by genomic instability 
in forms of chromosome instability and/or microsatellite 
instability [5]. Epigenetic effects of Cr(VI) which lead 
to altered histone methylation, histone acetylation, and 
DNA methylation have also been reported and believed 
to play significant roles in lung carcinogenesis [11, 12]. 
Despite these previous efforts, the specific mechanisms, 
particularly the specific intracellular molecular mediators 
of Cr(VI) carcinogenesis, remain poorly defined. 
DNA damage triggers phosphorylation of histone 
H2AX at Ser139 (γH2AX) by The ATM family protein 
kinases as part of the DNA damage response [13-15]. 
Generation of γH2AX is considered a hallmark of DNA 
double strand breaks (DSBs), the most detrimental form 
of DNA damage [16, 17]. The DNA damage response 
serves to initiate DNA repair or, in case of irreparable 
DNA damage, to eliminate cells carrying the damage 
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through apoptosis or senescence [13-15]. Improper DNA 
repair can lead to genomic instability, characterized by 
DNA mutations and/or chromosome instability [18]. It 
is conceivable that cellular components that affect the 
generation or repair of DNA damage can have important 
impact on genomic stability and carcinogenesis. 
Gene 33 is an inducible adaptor protein containing 
multiple domains for protein-protein interaction and 
signal transduction [19, 20]. The most significant function 
of Gene 33 characterized thus far is to bind to the kinase 
domain of ErbB receptor tyrosine kinases thereby 
inhibiting their kinase activities and the downstream 
signaling pathways [20-22]. Gene 33 can also induce 
apoptosis by activating the protein tyrosine kinase cAbl 
and inhibiting the ErbB-PI3K-AKT survival pathway [23, 
24]. Gene 33 may contribute to replicative and oncogene-
induced cell senescence through its inhibition of the 
EGFR signaling [25]. Gene 33 has also been shown to 
regulate cell migration through the HGF/c-Met signaling 
pathway [26]. Thus, Gene 33 regulates multiple signaling 
pathways that are important for tumorigenesis and tumor 
progression [27].
Increasing evidence supports a role of Gene 33 
as a bona fide tumor suppressor in the lung. Nonsense 
or missense mutations of gene 33 (errfi1) have been 
detected in lung cancers [28]. Reduced or loss of Gene 
33 expression has been reported in significant number of 
human lung cancer samples and cell lines [28, 29]. Gene 
33 null mice tend to develop spontaneous lung adenoma 
and adenocarcinoma [28, 30]. Gene 33 is located at 
chromosome 1p36.32 where loss of heterozygosity occurs 
frequently in lung cancer and associated with tobacco 
smoking [31]. 
Despite these findings, an assessment of its 
role in lung carcinogenesis in response to a relevant 
environmental lung carcinogen has not been conducted. 
Here we report that Gene 33 protein expression can be 
significantly suppressed by Cr(VI) in both lung epithelial 
(BEAS-2B) and lung cancer (A549) cells through both 
transcriptional and post-transcriptional mechanisms. 
Cr(VI) induces a DNA damage response, which occurs 
mainly in the S phase of the cell cycle. Knockdown 
of Gene 33 by siRNA elevates the Cr(VI)-induced 
DNA damage in BEAS-2B cells, which led to elevated 
micronucleus formation and cell transformation. Our 
data reveal a novel function of Gene 33 in regulating 
Cr(VI)-induced DNA damage and a potential involvement 
of this protein in Cr(VI)-mediated genotoxicity and 
carcinogenesis.
resUlts
cr(VI) suppresses Gene 33 expression
As reduced expression of tumor suppressor proteins 
is often associated with tumorigenesis, we checked 
whether the expression of tumor suppressor protein Gene 
33 is regulated by Cr(VI). We treated BEAS-2B cells 
with different concentrations of Cr(VI)(we used Na2CrO4 
throughout the study) for different periods of time. We 
observed that Cr(VI) suppressed the protein level of Gene 
33 in a dose- and time-dependent fashion, with significant 
inhibition started at 1μM and 24 hours, respectively 
(Figure 1A, 1B, 1C). A dose-dependent increase of 
γH2AX was also observed with significant elevation at 
2μM (Figure 1A). The activation of γH2AX indicates 
that Cr(VI) induces DNA damage in the form of DNA 
double strand breaks (DSBs), confirming the previously 
published observations [4, 6, 10, 32]. Figure 1D shows 
that Cr(VI) could further inhibit Gene 33 expression after 
Gene 33 knockdown by RNAi. Cr(VI) also inhibited Gene 
33 expression in A549 cells (Figure 1E). In both BEAS-
2B and A549 cells Gene 33 could be induced by bringing 
FBS content to 20% in normal DMEM (Figure 1D & 
1E), consistent with the finding that Gene 33 is a mitogen 
inducible protein [20, 24]. We further examined whether 
long term exposure to low concentrations of Cr(VI) also 
affects the level of Gene 33 protein. We treated BEAS-2B 
cells with 0.25 or 0.5 μM Cr(VI), two sub-lethal doses of 
Cr(VI) to BEAS-2B cells [33], for 2 months followed by 
checking the levels of Gene 33 protein. As shown in Figure 
1F, Cr(VI) treatments led to a dose-dependent reduction of 
Gene 33 protein levels in these cells. Collectively, our data 
demonstrate that the Gene 33 protein level is suppressible 
by Cr(VI) in lung epithelial and lung cancer cells.
Gene 33 expression is regulated at multiple levels 
by cr(VI)
We next studied how Cr(VI) regulates Gene 33 
expression. It is well documented that Cr(VI) generates 
the oxidative stress, which is likely the root cause of its 
toxicity [7]. We therefore checked whether suppression of 
the oxidative stress affects the level of Gene 33 protein. 
We find that N-acetylcysteine (NAC), a free radical 
scavenger, prevented the Cr(VI)-induced inhibition of the 
Gene 33 protein level at both 24 and 48 hours after Cr (VI) 
and NAC co-treatments. (Figure 2A). This result indicates 
that the inhibition of the Gene 33 protein level was caused 
by Cr(VI)-mediated generation of oxidative stresses rather 
than by direct action of Cr(VI). Of note, NAC alone was 
able to strongly inhibit Gene 33 expression (Figure 2A, 
NAC group). This would indicate that constitutive level 
of expression of this gene, in untreated cells, is facilitated 
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by endogenous oxidants. 
Gene 33 is an inducible protein whose expression 
is tightly controlled by mitogenic and stress signals [19, 
20]. In addition, Gene 33 contains two PEST domains 
suggesting that the ubiquitin/proteasome-mediated protein 
degradation mechanism may be involved in regulating the 
Gene 33 level [19, 20]. To explore this, we used MG132, 
an inhibitor of the 26S proteasome [34], to examine 
whether the proteasome-mediated protein degradation 
pathway plays a role in the observed reduction of Gene 33 
protein level upon Cr(VI) treatments. As expected, MG132 
was able to significantly raise the basal Gene 33 protein 
level in BEAS-2B cells (Figure 2B). However, MG132 
only modestly reversed the effect of Cr(VI) on Gene 33 
expression (Figure 2B). These data indicate that while 
Gene 33 is indeed subject to regulation by proteasome-
mediated pathway, the inhibition of Gene 33 expression by 
Cr(VI) can only be partially attributed to this mechanism. 
To further test this notion, we ectopically co-overexpressed 
FLAG-tagged Gene 33 with ubiquitin in BEAS-2B cells 
to see whether the ectopically expressed Gene 33 can be 
ubiquitinated by ectopically expressed ubiquitin. Indeed, 
as shown in Figure 2C, Gene 33 was ubiquitinated by 
ectopically expressed ubiquitin, as indicated by higher 
molecular weight proteins detected by anti-Gene 33 
antibody. Inhibition of the 26S proteasome by MG132 
Figure 1: cr(VI) suppresses the protein level of Gene 33. A. BEAS-2B cells were treated with the indicated concentrations of 
Cr(VI) for 72 hours and harvested for total cellular proteins with 1x sample buffer. Total cellular proteins were subjected to Western blot as 
described in Materials and Methods with antibodies toward the indicated proteins. GAPDH or β-actin was used a loading control. b. Same 
as A with 48h instead. c. BEAS-2B cells were treated with 5 μM Cr(VI) for indicated time periods and then processed as in A. D. BEAS-
2B cells were transfected with either a scrambled siRNA (control) or an siRNA targeting Gene 33 as described in Materials and Methods. 
Forty eight hour after transfection, cells were treated with 20% FBS (F) or Cr(VI) for additional 48 hours and processed as in A. e. A549 
cells were left untreated or treated with 20% FBS or 5 μM Cr(VI) for 48 hours. Cells were then processed as in A. F. BEAS-2B cells were 
cultured for 2 months (passed every three days) using media containing 0, 0.25, or 0.5 μM Cr(VI). Cells were harvested and processed at 
in A. 
Oncotarget8919www.impactjournals.com/oncotarget
elevated the level of Gene 33 ubiquitination (Figure 2C). 
Consistently, the Gene 33 protein level was strongly 
elevated by MG132. These data confirm that Gene 33 is 
indeed subjected to regulation by ubiquitin-proteasome 
system. However, albeit more modest compared to the 
endogenous Gene 33, Cr(VI) could still suppress the level 
of ectopically expressed Gene 33 protein with or without 
the presence of MG132, confirming that the proteasome-
mediated pathway may only partially responsible for 
the suppression. Moreover, Cr(VI) strongly reduced the 
level of ubiquitinated Gene 33 and inhibition of the 26S 
proteasome by MG132 did not significantly reverse this 
reduction (Figure 2C). These data are against the notion 
that Cr(VI) destabilizes the Gene 33 protein by enhancing 
its ubiquitination. Instead, they appears to suggest that 
Cr(VI) either activates a mechanism independent of the 
26S proteasome system to degrade the ubiquitinated Gene 
33 or Cr(VI) serves as a activator of the 26S proteasome 
that can partially overcomes the inhibitory effect of 
MG132, or both. 
As expected, ectopic expression of ubiquitin led to 
strong global ubiquitination of cellular proteins, showing 
as strong ubiquitin signals detected by the FLAG antibody 
(Figure 2D). Inhibition of the 26S proteasome by MG132 
strongly enhanced the global level of ubiquitination 
(Figure 2D). Of note, Cr(VI) appears to reduce the global 
ubiquitination with and without presence of MG132 
(Figure 2D). These data are consistent with above 
prediction that Cr(VI) activates an alternative mechanism 
or the 26S proteasome itself in a MG132-independent 
Figure 2: Gene 33 expression is regulated by cr(VI) through multiple mechanisms. A. BEAS-2B cells were either left 
untreated or treated with 5 μM Cr(VI), with or without presence of 20mM NAC for 24 or 48 hours. Cells were then harvested and Western 
blotted with antibodies toward the indicated proteins. b. BEAS-2B cells where left untreated or treated with 10μM MG132, 5 μM Cr(VI), 
or 10μM MG132 plus 5 μM Cr(VI) for 24 or 48 hours as indicated (MG132 was added 6 hours before the end of the treatment) . Cells 
were then processed as in A. c. BEAS-2B cells were co-transfected with plasmids containing FLAG-tagged Gene 33 and FLAG-tagged 
ubiquitin. Twenty fours later, cells were left untreated or treated with 5 μM Cr(VI), with or without presence of 10 μM MG132. Cells were 
then processed as in A. D. Total cellular proteins from C were Western blotted with an antibody toward FLAG. J. BEAS-2B cells were 
transfected with an miRNA mimics (Ctrl) or an miR200c inhibitor (200c). Seventy hours after transfection, the cells were treated with 
or without Cr(VI) for 48hours. The Gene33 expression levels were then determined by Western blot. Data are presented as mean +/- SD 
(E,F,H,I).
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fashion that degrades at least some ubiquitinated proteins. 
It appears that endogenous Gene 33 was more 
strongly inhibited by Cr(VI) than the ectopically expressed 
one (compare Figure 1 with Figure 2C). This suggests that 
transcriptional or other post-transcriptional mechanisms 
may also be involved in the regulation of the expression of 
the endogenous Gene 33. We therefore accessed whether 
Gene 33 is regulated by Cr(VI) at the mRNA level. Using 
real-Time PCR, we observed that Cr(VI) has a tendency to 
modestly inhibit the Gene 33 mRNA level in both BEAS-
2B and A549 cells, although significant inhibition only 
occurred at certain time points after treatments (Figure 2E 
and 2F). 
Given the relatively weak effect of Cr(VI) on Gene 
33 mRNA, we searched for other potential mechanisms. 
Gene 33 has been shown to be regulated by microRNAs, 
specifically miR-200 and miR-148 [35, 36]. We used 
TargetScan to search for potential microRNA targets on 
the 3’UTR of the Gene mRNA. As shown in Figure 2G, 
multiple potential targets for miR-200 family microRNAs 
present at the 3’UTR of Gene 33 mRNA, including those 
for miR-200b, miR-200c, and miR-429. We then measured 
the expression of miR-200b and miR-200c in BEAS-2B 
cells in response to Cr(VI) using real-Time PCR. We find 
that miR-200c but not miR-200b was modestly induced 
by Cr(VI) (Figure 2H and 2I), suggesting that miR-200c 
may contribute to suppression of Gene 33 by Cr(VI). 
To confirm this observation, we transfected a miR-200c 
inhibitor (Life Technologies) to see whether inhibition of 
miR-200c would overcome the suppression of Gene 33 
by Cr(VI). Surprisingly, while miR-200c strongly elevated 
the level of Gene 33 protein, it failed to overcome the 
inhibition by Cr(VI). These data indicate that the basal 
level of Gene 33 is indeed regulated by miR-200c but 
its suppression by Cr(VI) is not mediated by the modest 
induction of miR-200c in response to Cr(VI). Taken 
Figure 3: cr(VI) induces the DNA damage response. A. BEAS-2B cells were treated with 5 μM Cr(VI) for the indicated time 
periods. At the end of the treatments, total proteins were extracted from the cells and subjected to Western blot with antibodies against 
the indicated proteins. b. & c. BEAS-2B cells on chamber slides were treated with Cr(VI) at the indicated concentrations for 2 hours 
b. or 6 hours c. followed by LSC as described in Materials and Methods. The total levels of γH2AX and P-p53 were plotted against the 
concentration of Cr(VI). D. & e. Data from B and C were analyzed by splitting the cells in different phases of the cell cycle according to 
the DNA content. The levels of γH2AX D. or P-p53 e. in cells of different phases of the cell cycle were plotted against the concentration of 
Cr(VI). F. Examples of the readout of the cell cycle analysis showing percentages of cell in different phases of the cell cycle. G. Examples 
of the readout of the γH2AX measurement. 
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together, our data indicate that in lung epithelial and lung 
cancer cells Gene 33 expression are regulated by Cr(VI) 
through a combination of mRNA expression, protein 
degradation, and possibly other unidentified translational/
post translational mechanisms. 
cr(VI) induces DNA damage responses
Cr(VI) has been shown to induce DNA damage [2-
8]. To confirm this, we treated BEAS-2B cells with Cr(VI) 
and checked the level of γH2AX, a hallmark of DSBs 
[17], using Western blot. We find that the level of γH2AX 
was significant elevated upon Cr(VI) treatment for 6 and 
24 hours (Figure 3A). In contrast, 2 hour Cr(VI) treatment 
generate minimal amount of γH2AX. This time course is 
significantly slower than a typical chemotherapeutic drug 
that interferes with the DNA replication process, which 
generates a peak γH2AX response at within 2 hours 
[17, 37]. These results are consistent with the notion 
that Cr(VI) induces DNA damage indirectly through 
generation of oxidative stresses [7]. 
We next used Laser Scanning Cytometry (LSC) 
to further examine the effect of Cr(VI) on the DNA 
damage response in BEAS-2B cells. We observed that 
Cr(VI) had relatively weak effect on the γH2AX level 
at all Cr(VI) concentrations at 2 hour treatment while 
produced strong response at 6 hour (Figure 3B and 3C). 
In contrast, Camptothecin, a chemotherapeutic drug 
that inhibits Topoisomerase I (used as a positive control 
to detect H2AX phosphorylation) [37, 38], strongly 
increased the γH2AX level at both 2 and 6 hours (Figure 
3B and 3C). These data confirm our results using Western 
blot (Figure 3A). We also simultaneously measured the 
phosphorylation level of p53 at serine 15 (P-p53) in these 
experiments. Interestingly, there was a dose-dependent 
Figure 4: Gene 33 depletion elevates cr(VI)-induced DNA damage but does not affect cell cycle progression. A.-c. 
BEAS-2B A. & b. or A549 c. cells were transfected with scrambled (Ctrl) siRNA oligo or an siRNA oligo for Gene 33 (G33). Forty eight 
hours after transfection, cells were either left untreated or treated with 5 μM Cr(VI) for 6 hours (A&B) or 24 hours c. & D.. Cells were 
harvested for total proteins at the end of the treatments. Total protein lysates were subjected to Western blot with antibodies against the 
indicated proteins. D. & e. BEAS-2B cells transfected with either control or Gene 33 siRNA oligos as in A,B&C. Cells were then passed 48 
hours after transfection. Twenty four hours later, Cells were stained with DAPI followed by cell cycle analysis. Data are presented as mean 
+/- SD. An aliquot of cells from each transfection was collected for Western blot to check the protein level of Gene 33 (F). 
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reduction of P-p53 for the 2 hour treatment compared to 
a general increase for the 6 hour treatment, except at the 
20 μM concentration (Figure 3B and 3C). The differential 
behavior between γH2AX and P-p53 may reflect the fact 
that serine 15 of p53 is a target of a more diverse spectrum 
of kinases while H2AX is mainly phosphorylated by the 
ATM family kinases that are directly associated with DNA 
damage [16]. 
Further analysis of the data on the 6 hour treatment 
by separating different phases of the cell cycle reveals that 
γH2AX mainly presented at the S and G2/M phases of 
the cell cycle (Figure 3D). However, the dose-dependent 
increases in γH2AX were much more pronounced for cells 
in G1 and S phases than those in G2M phase (Figure 3D), 
indicating that Cr(VI)-induced DSBs mainly occur in the 
S and apparent the G1 phases of the cell cycle. However, 
we believe that the apparent strong induction of DSBs 
in cells of G1 phase actually caused by cells entering S 
phase (see Discussion). In contrast to γH2AX, the dose-
dependent changes in P-p53 were similar among different 
phases (Figure 3E). Cr(VI) treatment also led to cell cycle 
arrest at the G1 phase of the cell cycle in a dose-dependent 
fashion (Figure 3F). Figure 3G shows sample readouts of 
LSC. 
Gene 33 knockdown promotes cr(VI)-induced 
DNA damage
Given that Cr(VI) suppresses Gene 33 expression 
and induces DNA damage, we checked whether Gene 
33 plays a role in Cr(VI)-induced DNA damage. We 
transiently knockdown Gene 33 using siRNA and 
measured its effect on the Cr(VI)-induced DNA damage 
response. We find that knockdown of Gene 33 in BEAS-
2B cells elevated the level of Cr(VI)-induced DNA 
damage, as indicated by increased γH2AX signals in cells 
transfected with an siRNA oligo for Gene 33 compared 
to those transfected with a scrambled oligo (Figure 4A, 
4B, 4C, 4D). This effect occurred after both 6 hour and 24 
hour Cr(VI) treatments (Figure 4A, 4B, 4C). In contrast, 
while Cr(VI) strongly induced P-p53, Gene 33 knockdown 
had limited effect on this phosphorylation (Figure 4A and 
4C). We also checked the activities of p38 and ERK by 
measuring their phosphorylation levels as these kinases 
have been implicated in the phosphorylation of p53 
in response to Cr(VI) in A549 cells [39]. We find that 
while Gene 33 knockdown slightly increased the level of 
phospho-p38, the Cr(VI) treatments had limited effect on 
it (Figure 4A). The level of phosphorylated ERK appeared 
the same among different treatments (Figure 4A). A 
similar effect of Gene 33 on γH2AX was also observed in 
A549 cells, where Gene 33 knockdown also enhanced the 
level of γH2AX in response to Cr(VI) treatment (Figure 
4D). Of note, γH2AX signals in A549 cells appeared to be 
weaker at both the basal level and in response to Cr(VI) 
treatments (Figure 4D). In addition, we could hardly detect 
the P-p53 signal in A549 cells with or without Cr(VI) 
treatment (Figure 4D). These data suggest that A549 may 
be more resistant to Cr(VI)-induced DNA damage than 
BEAS-2B cells. We also find that Gene 33 knockdown 
alone had limited effect on cell cycle progression of 
BEAS-2B cells under normal growth condition (Figure 
4E and 4F). Collectively, our data indicate that Gene 33 
inhibits Cr(VI)-induced DNA damage in lung epithelial 
and lung cancer cells. 
Gene 33 ablation enhances cr(VI)-induced 
micronucleus formation
Cr(VI) has been shown to induce chromosome 
instability in form of micronucleus formation in both 
cellular and animal models [32, 40]. Since Cr(VI) is 
considered a weak mutagen, induction of chromosome 
instability is believed to be the main mechanism leading 
to genomic instability and carcinogenesis [5]. Given 
the effect of Gene 33 on Cr(VI) induced DNA damage 
we wanted to examine whether Gene 33 affects Cr(VI)-
induced formation of micronuclei, an indication of 
DNA damage-induced chromosome instability [41]. 
We transiently knocked down Gene 33 with siRNA in 
BEAS-2B cells and assessed its effect on the level of 
micronucleus formation induced by Cr(VI). The result 
shows that the combination of Gene 33 knockdown and 
Cr(VI) treatment led to statistically significant increase in 
the MN level (Figure 5A). Figure 5B and 5C show Gene 
33 knockdown by siRNA and examples of MN. Our data 
are in line with the notion that Gene 33 regulates Cr(VI)-
induced DNA damage that lead to chromosome instability 
in lung epithelial cells. 
Gene 33 deletion increases cr(VI)-induced cell 
transformation
The initial biological step of lung carcinogenesis is 
the malignant transformation of lung epithelial cells. Given 
the effect of Gene 33 on DNA damage and chromosome 
instability, it is likely that Gene 33 regulate Cr(VI)-induced 
lung epithelial cell transformation. We checked how the 
Gene 33 expression level affects anchorage-independent 
cell growth, a hallmark of cell transformation, in BEAS-
2B cells using standard soft agar colony formation assay. 
Cr(VI) has been well documented to be capable of 
transforming BEAS-2B cells [33, 42, 43]. To confirm this, 
we treated BEAS-2B cells with Cr(VI) at 0.25 and 0.5 μM 
concentrations (both are sub-lethal concentrations) [33] 
followed by soft agar colony formation assay as described 
in Materials and Methods. As shown in Figure 6A, there 
were significant and dose-dependent increases in numbers 
of colonies formed after Cr(VI) treatments, confirming 
the previously published findings [33]. Of note, BEAS-
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2B cells are known to have a basal ability of forming 
small colonies in soft agar assay [33]. We next compared 
levels of Cr(VI)-induced transformation of BEAS-2B 
cells with or without stable Gene 33 knockdown using 
the same experimental protocol. We find that cells with 
stable Gene 33 knockdown exhibited significantly higher 
levels of colony formation both at the basal condition and 
after Cr(VI) treatments (Figure 6C). Figure 6D shows the 
significant lower level of Gene 33 expression in BEAS-2B 
cell with stable Gene 33 knockdown before transformation 
experiment. Our data establish that Gene 33 suppresses 
Cr(VI)-induced lung epithelial cell transformation, 
consistent with the observation that endogenous Gene 33 
reduces DNA damage and inhibits chromosome instability 
elicited by Cr(VI). 
Figure 5: Gene 33 depletion enhances cr(VI)-induced micronucleus formation in beAs-2b cells. A. Cytokinesis-block 
micronucleus assay were performed as described in Materials and Methods. Asterisk indicates statistically significant. Data are presented 
as mean +/- SD. b. Cells were harvested 48 hours after transfection of siRNA oligos and subjected to Western blot to check the expression 
of Gene 33. GAPDH was used as a loading control. c. Representative images showing micronuclei associated with di-nuclei. 
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DIscUssION
The cellular effects of Cr(VI) are primarily caused 
by the generation free radicals [7]. The relatively non-
specific nature of free radicals implies that Cr(VI) likely 
alters multiple cellular activities, as indicated by studies 
on gene expression profiles [33, 44-46]. Accordingly, 
pathways that control cell proliferation, growth, survival, 
autophagy, as well as DNA damage and repair have all 
been shown to be part of the cellular responses to Cr(VI) 
[2]. Moreover, recent studies suggest that the PI3K/AKT/
GSK3/β-catenin and the EGFR signaling pathways are 
important for Cr(VI)-induced BEAS-2B lung epithelial 
cell transformation [47, 48]. Given the complexity the 
regulation, it is crucial to identify the molecular players 
that drive Cr(VI)-induced lung carcinogenesis rather than 
those associated only with the transient stress responses.
The present study provides evidence for a novel 
association of the adaptor protein Gene 33 in Cr(VI)-
induced lung epithelial cell transformation and reveals 
a previously unidentified function of this protein in the 
DNA damage response. We find that the Gene 33 level 
can be inhibited by Cr(VI) exposure in lung epithelial and 
lung cancer cells at the protein level and to a less extent 
the mRNA level. We show that Gene 33 inhibits DNA 
damage induced by Cr(VI). We further demonstrate that 
Gene 33 inhibits Cr(VI)-induced MN formation and cell 
transformation in lung epithelial cells. 
Our data reveal that the root cause of the 
suppression of Gene 33 by Cr(VI) is the generation of free 
radicals (Figure 2A). These free radicals are apparently 
able to inhibit Gene 33 at both the protein and mRNA 
levels (Figures 1 and 2). The 26S proteasome system is 
clearly involved in the Cr(VI) suppression of the Gene 
33 protein level (Figure 2A, 2B, 2C). However, the effect 
of Cr(VI) on ubiquitination of Gene 33 is interesting as 
Cr(VI) inhibits rather than enhance Gene 33 ubiquitination 
(Figure 2C). Cr(VI) also inhibits the ubiquitination of 
many other cellular proteins (Figure 2D). These data 
do not support the notion that Cr(VI) promotes Gene 
Figure 6: Gene 33 depletion enhances cr(VI)-induced cell transformation in beAs-2b cells. Anchorage-independent cell 
growth measured by soft agar colony formation assay was used as a measure of cell transformation. A. BEAS-2B cells were cultured with 
media containing Cr(VI) of the indicated concentrations for 5 weeks before performing soft agar colony formation assay as described in 
Materials and Methods. b. Examples of the colonies from A are shown. c. BEAS-2B cells stably transfected with a scrambled C. or Gene 
33 (G33) shRNA plasmids (Sigma) were cultured with media containing 0.5μM of Cr(VI) for 5 weeks before conducting soft agar colony 
formation assay as described in Materials and Methods. D. Western blot showing the expression of the Gene 33 in cells stably transfected 
with scrambled C. or Gene 33 shRNA used in in C. Data are presented as mean +/- SD (A&C).
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33 degradation by enhancing its ubiquitination. Instead, 
Cr(VI) appears to suppress Gene 33 protein, at least 
partially, through a ubiquitin-dependent but proteasome-
independent pathway or by activating the proteasome 
itself. Further investigation into this question is clearly 
needed. 
The finding that inhibition of miR-200c strongly 
elevates the Gene 33 protein level is consistent with 
the existence of multiple consensus binding element 
for miR200 and the previous findings (Figure 2G) [35]. 
However, we did not detect a role of miR-200c in Cr(VI)-
mediated suppression of Gene 33 despite the increase in 
miR-200c expression upon Cr(VI) treatment (Figure 2G 
and 2I). 
A recent study suggests that Cr(VI)-induced DSBs 
accumulate at the euchromatin region where active 
transcription occurs [10]. These events likely slow down 
transcription of many genes. Whether Gene 33 is one on 
the genes that is suppressed by this mechanism remains to 
be determined. In addition, epigenetic modifications could 
also supress Gene 33 expression, especially in chronic 
setting. Further research in this direction is needed. 
It has been shown that Cr(VI)-induced DSBs mainly 
happen at the S phase of the cell cycle as a result of the 
formation of Cr(III)-DNA adducts during Cr(VI) reduction 
process [2]. Our data confirm this notion. However, our 
results also seem to suggest that cells in G1 phase are also 
sensitive to Cr(VI)-induced DSBs. Since DNA damage 
induced by genotoxic agent typically happens during DNA 
replication in S phase [37], the apparent increase in the 
level of γH2AX in cells in G1 phase likely reflected DNA 
damage in cells entering the S phase when their DNA 
content was not appreciably increased comparing to G1 
cells. This is similar to the cells treated with Camptothecin 
(Figure 3G), the drug that induces γH2AX exclusively 
in S phase [37]. Indeed, our experiment on the effect 
of Cr(VI) in A549 cells confirmed this notion (Figure 
S1 and the discussion therein ). The high basal level of 
γH2AX in G2/M phase observed in our experiments 
was likely a result of DNA damage-independent mitotic 
phosphorylation of H2AX [49, 50]. Consistently, the 
γH2AX level was less affected by Cr(VI) during G2/M 
Figure 7: Proposed model for Gene 33 in cr(VI)-induced lung carcinogenesis. Cr(VI) reduces the levels of Gene 33 mRNA and 
protein thereby inhibiting Cr(VI)-induced DNA damage that lead to genomic instability, cell transformation and carcinogenesis. Gene 33 
may also reduce lung carcinogenesis by inhibiting lung epithelial cell proliferation, promoting apoptosis, and slowing down cell migration. 
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phase (Figure 3D). 
We find that P-p53 behaved differently between 
2 hour and 6 hour treatments with Cr(VI): a dose-
dependent reduction vs. a dose-dependent increase except 
at 20 μM (Figure 3B and 3C). These data, coupled with 
those showing limited increase in the level of γH2AX in 
response to Cr(VI) at 2 hours vs. strong increase in the 
level of γH2AX at 6 hours, suggest that the kinase that 
was responsible for the basal phosphorylation of p53 was 
inhibited by Cr(VI) at the initial period of the treatment 
before DNA damage occurs. Our results show that the 
activities of p38 and ERK MAPK kinases, indicated 
by the levels of p38 and ERK phosphorylation, were 
mostly unchanged by 6 hour Cr(VI) treatment (Figure 
4A). Although these two kinases have been shown to 
phosphorylate p53 at Serine 15 [51], our data do not 
support roles of these kinases in phosphorylation of p53 
at serine 15 in response to Cr(VI). Of note, it has been 
reported that ERK phosphorylates p53 at serine 15 in 
response to Cr(VI) in A549 cells, albeit at a much higher 
concentration (50μM)[39]. Moreover, we were unable 
to detect any signal of P-p53 in A549 cells after 24 hour 
treatment with 5 μM Cr(VI) (Figure 4D). Thus, a cell type- 
or dose-dependent discrepancy likely exists. 
Our observation that depletion of Gene 33 protein 
significantly elevates Cr(VI)-induced DSBs (Figure 
4) suggests Gene 33 may either function to prevent 
Cr(VI)-induced DNA damage or to facilitate DNA repair 
following the DNA damage. We also observed that 
Gene 33 depletion led to dramatically elevated levels of 
ubiquitinated γH2AX upon Cr(VI) treatment (Figure 4A 
and 4B), consistent with the notion that ubiquitinated 
H2AX is associated with the DNA damage response [52]. 
Our data showing that Gene 33 can suppress Cr(VI)-
induced micronucleus formation and cell transformation 
is consistent with the notion that Gene 33 functions to 
inhibit Cr(VI)-mediated DNA damage and chromosome 
instability. 
The mechanism underlying the regulation of 
Cr(VI)-induced DNA damage by Gene 33 is unclear. It 
has been shown that EGFR translocates to the nucleus 
after certain genotoxic insults and facilitates DNA repair 
by activating DNA-PK and phosphorylating histone 
H4 [53-55]. As Gene 33 is a well-established regulator 
of the EGFR kinase activity and its internalization [21, 
22, 56, 57], it is tempting to speculate that Gene 33 may 
modulate EGFR nuclear translocation to and/or activity 
in the nucleus thereby regulating the DNA repair process. 
Our experiments indeed show that Gene 33 is capable 
of affecting the interaction of EGFR with DNA-PK and 
histone H4 (SP and DX, unpublished observations). 
Further in-depth investigation into this mechanism is 
currently underway. 
The effect of Gene 33 on canonical EGFR signaling 
pathway may also need to be taken into consideration 
when evaluating its role in Cr(VI) carcinogenesis. 
Our data show that Gene 33 knockdown had limited effect 
on cell cycle progression in BEAS-2B cells cultured in 
medium containing 10% FBS (Figure 4E and 4F). Since 
Gene 33 is a specific inhibitor of EGFR family receptor 
tyrosine kinases [20-22, 58], it is conceivable that while 
Gene 33 can significantly inhibit EGF-induced cell cycle 
entry under serum deprivation [20], its role in cell cycle 
progression in presence of 10% FBS may be limited. 
However, long term increase in EGFR signaling likely 
contributes to higher potential for cell transformation. 
Accordingly, elevated activity of the EGFR signaling 
pathway as a result of increased expression of EGFR has 
been reported in Cr(VI)-transformed BEAS-2B cells [48]. 
The inhibition of Gene 33 expression by Cr(VI) would 
be consistent with the increased EGFR expression and 
EGFR signaling as Gene 33 inhibits EGFR kinase activity 
and promotes EGFR degradation [57, 58]. It will be 
interesting to determine whether the reduced expression 
of Gene 33 contributes to the elevated EGFR signaling 
in Cr(VI)-transformed lung epithelial cells. Furthermore, 
the involvement of other known functions of Gene 33 
in cell apoptosis, cell senescence, and cell migration in 
Cr(VI)-mediated cell transformation and tumorigenesis 
also warrants further investigation.
Taken together, the present study implicates Gene 33 
as an important player in Cr(VI)-induced lung epithelial 
transformation and lung carcinogenesis. Although these 
findings are confirmative of the previous view that Gene 
33 is a tumor suppressor protein, this is the first study 
linking Gene 33 to potential lung malignancy induced 
by an environmental and occupational carcinogen. In 
addition, we explored the mechanism underlying the 
suppression of Gene 33 expression by Cr(VI). Moreover, 
we have identified a novel association of Gene 33 with 
Cr(VI)-induced DNA damage. We propose a model on 
the potential role of Gene 33 in Cr(VI)-induced lung 
carcinogenesis: 1. Cr(VI) inhibits Gene 33 expression 
at both mRNA and protein levels. 2. Gene 33 inhibits 
Cr(VI)-induced DNA damage, genomic instability, cell 
neoplastic transformation, and likely carcinogenesis. 3. 
This mechanism, together with other functions of Gene 
33 in cell proliferation, apoptosis, and cell migration, 
constitutes the overall role of Gene 33 in Cr(VI)-induced 
lung carcinogenesis (Figure 7). 
MAterIAls AND MethODs
cell lines, antibodies, and plasmids
BEAS-2B human lung bronchial epithelial cells 
and A549 human lung adenocarcinoma cells were 
obtained from American Type Culture Collection. Cells 
were cultured in DMEM supplemented with 10% fetal 
bovine serum (FBS) and antibiotics (100 unit/ml of 
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penicillin and 100 μg/ml of streptomycin sulfate per 
mL) under 5% CO2 condition. The antibody to Gene 33 
has been described previously [20, 24]. The antibody 
to γH2AX was purchased from Biolegend. Antibodies 
to GAPDH, EGFR, and β-actin were purchased from 
Santa Cruz Biotechnology. The antibody to P-p53 (S15) 
was purchased from Cell Signaling Technology. The 
mammalian expression plasmid encoding FLAG-tagged 
Gene 33 have been described previously [20]. The 
mammalian expression plasmid encoding FLAG-tagged 
ubiquitin was a generous gift from Dr. Wei Dai at New 
York University School of Medicine. 
Western bolt
Standard Western blot procedure was using 
throughout the study. SDS-PAGE was carried out using 
the mini gel system from Bio-Rad. Proteins in gels were 
then transferred to PVDF membrane. After blocking with 
TBST containing 5% non-fat dry milk, the membrane 
was incubated overnight with primary antibodies diluted 
with TBST containing 5% BSA using dilutions suggested 
by the manufacturers. After thorough wash with TBST, 
the membrane was further incubated with horse radish 
peroxidase-conjugated secondary antibodies for 1 hour 
at room temperature followed by thorough washing 
with TBST buffer. The signals on the membrane were 
developed with an ECL system (Pierce).
Immunoprecipitation
Cells were lysed in the RIPA buffer supplemented 
with protease and phosphatase inhibitors. The lysates were 
then centrifuged for 30 min at >10000g. The supernatants 
were kept as total cell lysates. One μg of the antibody 
and 40 μl of protein G Agarose resin (50/50, Upstate 
Biotechnology) were then added to 1 mg of each cell 
lysates and incubated at 4ºC for overnight followed by 
extensively washing with the lysis buffer. Proteins bond to 
the resin were then extracted with SDS sample buffer and 
subjected to SDS-PAGE followed by Western blot with 
appropriate antibodies. 
laser scanning cytometry
Cells were cultured on 2-well chamber slides. 
After treatments, cells were fixed with 1% formaldehyde 
followed by 70% ethanol, pemmeabilized with 0.1% triton 
X100, blocked with 1% BSA, and immunostained with 
primary antibodies to both γH2AX and phospho-p53 (S15) 
followed by fluorescent-conjugated secondary antibodies 
together with DAPI. The cells were then analyzed with 
CompuCyte four laser iCys scanning cytometer. 
real-time Pcr
Cells were treated and harvest for total RNAs 
with Trizol reagent (Life technologies). Total RNAs 
were converted to cDNA using a RT-PCR kit (Clontech) 
and subjected to real-time PCR using SYBR Green 
master mix (Clontech) and a real-time PCR machine 
(StratageneMx3005P). The primers used are follows: 
Gene 33: 5’-CTGGAGCAGTCGCAGTGAG-3’/ 
5’-GCCATTCATCGGAGCAGATTTG-3’, 
GAPDH (as internal control): 
5’-ACAACTTTGGTATCGTGGAAGG-3’/ 
5’-GCCATCACGCCACAGTTTC-3’ real-time PCRs for 
microRNAs were carried out using miScript Primer Assay 
(Qiagen) according to manufacturer’s instructions. The 
results were corrected for U6.
rNAi and microrNA
For transient RNAi, cells were cultured to 70% 
confluence and transfected with scrambled or Gene 33 
siRNA oligos (Dharmacon) using Lipofectamine 2000 
according to manufacturer provided protocol. Cells were 
analyzed at least 48h post-transfection. For microRNA 
inhibition, a negative control or a miR-200c microRNA 
inhibitor (Dharmacon) was transfected (at 25 nM) using 
Lipofectamine RNAiMAX reagent (Life technology) 
and analyzed 24 hours after transfection. For stable 
knockdown, shRNA constructs containing scrambled or 
Gene 33 (Sigma-Aldrich) were transfected into BEAS-
2B cells using Lipofectamine 2000 (Life technology) 
followed by selection with puromycin. 
cytokinesis-block micronucleus assay
BEAS-2B cells growing on a 6 well plate were 
transfected with scrambled or Gene 33 siRNA oligos. 
Forty eight hours after transfection, cells were passed to 
2-well chamber slides. Twenty four hours later, cells were 
treated with cytochalasin B (9µg/ml) for additional 24h 
with or without co-treatment with1µM Na2CrO4. At the 
end of the treatments, cells were fixed in 1% formaldehyde 
and stained with DAPI (2.85µg/ml). Numbers of 
micronuclei in 1000 binucleated cells were scored under a 
fluorescence microscope and the ratio of micronuclei and 
binucleated cells were presented as percentage. 
soft agar colony formation assay
Cells were plated in 0.3% top agar medium on 0.5 % 
bottom agar medium in 6-well plates (5,000 cells/well) in 
triplicates. The plates were incubated at 37˚C for 4 weeks. 
At the end of the incubation, plates were staining with 
Crystal Violet and air-dry. Total numbers of colonies in 
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each well were then counted. 
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